CHEBI:32168 - sulpiride

Main ChEBI Ontology Automatic Xrefs Reactions Pathways Models
ChEBI Name sulpiride
ChEBI ID CHEBI:32168
Definition A member of the class of benzamides obtained from formal condensation between the carboxy group of 2-methoxy-5-sulfamoylbenzoic acid and the primary amino group of (1-ethylpyrrolidin-2-yl)methylamine.
Stars This entity has been manually annotated by the ChEBI Team.
Supplier Information
Download Molfile XML SDF
Wikipedia License
Waiting for wikipedia content
Read full article at Wikipedia
Formula C15H23N3O4S
Net Charge 0
Average Mass 341.42600
Monoisotopic Mass 341.14093
InChI InChI=1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)
InChIKey BGRJTUBHPOOWDU-UHFFFAOYSA-N
SMILES CCN1CCCC1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O
Roles Classification
Chemical Role(s): Bronsted base
A molecular entity capable of accepting a hydron from a donor (Bronsted acid).
(via organic amino compound )
Biological Role(s): dopaminergic antagonist
A drug that binds to but does not activate dopamine receptors, thereby blocking the actions of dopamine or exogenous agonists.
Application(s): antidepressant
Antidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions.
antiemetic
A drug used to prevent nausea or vomiting. An antiemetic may act by a wide range of mechanisms: it might affect the medullary control centres (the vomiting centre and the chemoreceptive trigger zone) or affect the peripheral receptors.
antipsychotic agent
Antipsychotic drugs are agents that control agitated psychotic behaviour, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect.
dopaminergic antagonist
A drug that binds to but does not activate dopamine receptors, thereby blocking the actions of dopamine or exogenous agonists.
View more via ChEBI Ontology
ChEBI Ontology
Outgoing sulpiride (CHEBI:32168) has role antidepressant (CHEBI:35469)
sulpiride (CHEBI:32168) has role antiemetic (CHEBI:50919)
sulpiride (CHEBI:32168) has role antipsychotic agent (CHEBI:35476)
sulpiride (CHEBI:32168) has role dopaminergic antagonist (CHEBI:48561)
sulpiride (CHEBI:32168) is a N-alkylpyrrolidine (CHEBI:46775)
sulpiride (CHEBI:32168) is a benzamides (CHEBI:22702)
sulpiride (CHEBI:32168) is a sulfonamide (CHEBI:35358)
Incoming (R)-(+)-sulpiride (CHEBI:64122) is a sulpiride (CHEBI:32168)
(S)-(−)-sulpiride (CHEBI:64119) is a sulpiride (CHEBI:32168)
IUPAC Name
N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxy-5-sulfamoylbenzamide
INNs Sources
sulpirida DrugBank
sulpiride KEGG DRUG
sulpiridum DrugBank
Synonyms Sources
(±)-sulpiride NIST Chemistry WebBook
5-(Aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxybenzamide ChemIDplus
N-((1-Ethyl-2-pyrrolidinyl)methyl)-2-methoxy-5-sulfamoylbenzamide ChemIDplus
N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-o-anisamide ChemIDplus
Sulpirid DrugBank
Sulpyrid DrugBank
Manual Xrefs Databases
2537 DrugCentral
D01226 KEGG DRUG
DB00391 DrugBank
DE2903891 Patent
LSM-5080 LINCS
Sulpiride Wikipedia
US3342826 Patent
View more database links
Registry Numbers Types Sources
15676-16-1 CAS Registry Number ChemIDplus
15676-16-1 CAS Registry Number KEGG DRUG
15676-16-1 CAS Registry Number NIST Chemistry WebBook
494008 Reaxys Registry Number Reaxys
Citations Waiting for Citations Types Sources
16327907 PubMed citation Europe PMC
16924461 PubMed citation Europe PMC
17912501 PubMed citation Europe PMC
17942035 PubMed citation Europe PMC
18757738 PubMed citation Europe PMC
18985321 PubMed citation Europe PMC
19370694 PubMed citation Europe PMC
19546258 PubMed citation Europe PMC
19672580 PubMed citation Europe PMC
19864199 PubMed citation Europe PMC
19941957 PubMed citation Europe PMC
20061345 PubMed citation Europe PMC
20091661 PubMed citation Europe PMC
20177884 PubMed citation Europe PMC
20304506 PubMed citation Europe PMC
20305607 PubMed citation Europe PMC
20538381 PubMed citation Europe PMC
20599913 PubMed citation Europe PMC
20875676 PubMed citation Europe PMC
Last Modified
22 February 2017